GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
July 25 2023 - 9:00AM
- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),
a medical device and digital health platform company focused on
diabetes and prediabetes, announced today the completion and
positive results of its feasibility study for its implantable
continuous glucose monitor technology for patients with Type 1 and
Type 2 insulin-dependent diabetes.
The primary goal of the feasibility study was to
demonstrate that the CGM sensor design could reliably report
glucose measurements for two years post-implant. Laboratory bench
testing confirmed that a minimum two-year implant longevity is
highly probable with the current sensor design. The implant
longevity was independently verified by a third-party using sensor
parameters to simulate sensor performance over time.
Given the positive results of the study, the
Company is now preparing for long-term animal studies, which are
expected to begin later this year.
“We are pleased to have met our goal to
confidently project a long-term sensor life that is at least four
times longer than what is currently available for an implantable
CGM, without the requirement for external wearables or frequent
calibrations.” said Paul Goode, CEO of Glucotrack. “We
look forward to the animal study as the next development step of
this exciting technology that can help improve the lives of so
many.”
Glucotrack is committed to commercializing an
implantable CGM with long-term sensor life with no requirement for
any additional wearable component, and a once-only calibration. The
Company believes that these will be key differentiators as compared
to other continuous glucose monitors, either currently on the
market or known to be in development.
About Glucotrack,
Inc.
Glucotrack, Inc. (NASDAQ: GCTK), (formerly known
as Integrity Applications, Inc.) is focused on the design,
development, and commercialization of novel technologies for people
with diabetes and prediabetes. The Company’s initial product,
Glucotrack®, is a proprietary non-invasive glucose monitoring
device designed to obtain glucose level measurements without the
pain, incremental cost, difficulty, or discomfort of conventional
invasive finger stick devices. For more information, please visit
and http://www.glucotrack.com.
Investor Contact: investors@glucotrack.com
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “expect”, “plan” and “will” are intended
to identify forward-looking statements. Readers are cautioned that
certain important factors may affect Glucotrack’s actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect Glucotrack’s results include, but are not
limited to, the ability of GlucoTrack to raise additional capital
to finance its operations (whether through public or private equity
offerings, debt financings, strategic collaborations or otherwise);
risks relating to the receipt (and timing) of regulatory approvals
(including FDA approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to its
current and future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2022 as filed with the SEC on March
31, 2023.
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From Apr 2024 to May 2024
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From May 2023 to May 2024